3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Hepatocellular
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
1
Liver Neoplasms
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
12
Magnetic Resonance Spectroscopy
11
Specimen Handling
10
pembrolizumab
8
Cisplatin
8
enfortumab vedotin
5
Radiation
5
Mitomycin
5
Fluorouracil
5
avelumab
4
Cystoscopy
4
durvalumab
3
dehydroftorafur
3
Transurethral Resection of Bladder
3
Radiotherapy
3
Platinum
3
Nivolumab
3
Mitozytrex
3
Cystectomy
3
1,2-diaminocyclohexaneplatinum II citrate
3
ulixertinib
2
tremelimumab
2
erdafitinib
2
cabozantinib
2
atezolizumab
2
X-Rays
2
Paclitaxel
2
Immunoglobulin G
2
Docetaxel
2
Disulfides
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
tremelimumab
×
30 days
×
Clear all
NCT04960709
2026-06-04
VOLGA
AstraZeneca
Phase 3
Active not recruiting
712 enrolled
NCT03682068
2026-05-28
NILE
AstraZeneca
Phase 3
Active not recruiting
1,246 enrolled